<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193452</url>
  </required_header>
  <id_info>
    <org_study_id>SL-eCRC</org_study_id>
    <nct_id>NCT01193452</nct_id>
  </id_info>
  <brief_title>S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Comparing S-1/Leucovorin With sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial on the assumption that S-1 combined with Leucovorin may have better&#xD;
      efficacy and safety than simplified 5-FU/LV infusion therapy in elderly patients with&#xD;
      advanced colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase Ⅱ study, in which S-1 is used in combination with leucovorin in&#xD;
      elderly patients with advanced colorectal cancer as first-line treatment,comparing with&#xD;
      sLV5FU2 therapy. The aim of this study is to determine the efficacy and safety of S-1/LV in&#xD;
      elderly patients in the first-line setting. The other secondary endpoints are progression&#xD;
      free survival,overall survival, and quality of life are also evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>S-1/LV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 combined with Leucovorin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sLV5FU2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-FU/LV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1, Leucovorin</intervention_name>
    <description>S-1 :&#xD;
The initial dosage of S-1 is determined by the body surface area:&#xD;
Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day&#xD;
Leucovorin:&#xD;
25mg twice per day po.&#xD;
The treatment is given for one week,and no chemotherapy is given for the following one week.</description>
    <arm_group_label>S-1/LV</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin, 5-fluorouracil</intervention_name>
    <description>leucovorin: 400mg/m2 intravenous infusion d1;&#xD;
5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours&#xD;
repeat every 2 weeks</description>
    <arm_group_label>sLV5FU2</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Oral medication is acceptable&#xD;
&#xD;
          -  Histologically confirmed colorectal carcinoma&#xD;
&#xD;
          -  Male or female ≥ 65 years of age&#xD;
&#xD;
          -  No prior chemotherapy,radiotherapy,target therapy and immunotherapy, except adjuvant&#xD;
             chemotherapy with an interval of ≥ 180 days)&#xD;
&#xD;
          -  Presence of at least one target lesion measurable by CT scan or MRI,within 15 days&#xD;
             prior to trial&#xD;
&#xD;
          -  The lab values within 2 weeks prior to trial should meet:&#xD;
&#xD;
        PLT ≥7.5*10^4/mm3 ANC≥2000/mm3 HB≥100g/L Total bilirubin &lt; upper limit of normal level&#xD;
        ALT/AST/ALP &lt; 2.5 x UNL (&lt;5 x UNL for patients with liver or bone metastasis) Serum&#xD;
        creatinine &lt; UNL&#xD;
&#xD;
          -  Performance status (ECOG) 0~1&#xD;
&#xD;
          -  Life expectation longer than 90 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to S-1,fluorouracil or leucovorin&#xD;
&#xD;
          -  Any investigational agent(s) within 4 weeks prior to entry&#xD;
&#xD;
          -  Previous or currently exposure to certain drugs which are proved to have influence on&#xD;
             blood drug concentration&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Severe organ failures or diseases, including: intestinal obstruction, pulmonary&#xD;
             fibrosis, uncontrolled diabetes mellitus,clinically relevant coronary disease,&#xD;
             cardiovascular disorder or myocardial infarction,renal or liver failure, severe&#xD;
             psychiatric illness,cerebral vascular disease and sever GI ulcer which need blood&#xD;
             infusion.&#xD;
&#xD;
          -  Uncontrolled hydrothorax,ascites and hydropericardium&#xD;
&#xD;
          -  Multiple bone metastatic lesions&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Chronic diarrhea or digestive disfunction&#xD;
&#xD;
          -  Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin&#xD;
             or pre-invasive carcinoma of the cervix with adequate treatment)&#xD;
&#xD;
          -  Strong willingness to receive surgery or highly potential to have intestinal&#xD;
             obstruction which may need surgery intervention&#xD;
&#xD;
          -  Other conditions that primary investigate or investigator consider to be unsuitable&#xD;
             for the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Li, MD,PhD</last_name>
    <phone>64175590</phone>
    <phone_ext>5100</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenhua Li, MS</last_name>
    <phone>64175590</phone>
    <phone_ext>8900</phone_ext>
    <email>whliiris@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jin Li'</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, MD,PhD</last_name>
      <phone>8621 64175590</phone>
      <phone_ext>5100</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Wenhua Li, MS</last_name>
      <phone>862164175590</phone>
      <phone_ext>8900</phone_ext>
      <email>whliiris@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wen Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>September 1, 2010</last_update_submitted>
  <last_update_submitted_qc>September 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jin Li</name_title>
    <organization>Fudan University Shanghai Cancer Center</organization>
  </responsible_party>
  <keyword>elderly patients</keyword>
  <keyword>advanced colorectal cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>S-1</keyword>
  <keyword>5-fluorouracil</keyword>
  <keyword>leucovorin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

